Home/Pipeline/SNAP-CAR Solid Tumor Programs

SNAP-CAR Solid Tumor Programs

Solid Tumors

Discovery/PreclinicalResearch Stage

Key Facts

Indication

Solid Tumors

Phase

Discovery/Preclinical

Status

Research Stage

Company

Coeptis Therapeutics

About Coeptis Therapeutics

Coeptis Therapeutics is advancing a differentiated pipeline of engineered cell therapies focused on overcoming the major challenges of antigen escape and treatment accessibility in oncology. Its core technologies include SNAP-CAR, a multi-antigen targeting CAR-T platform, and DARIC, a universal, multi-donor NK cell platform. The company is progressing its lead asset, COEP-001 (SNAP-CAR CD19), into clinical development for B-cell malignancies, positioning itself in the competitive but high-potential cell therapy market. As a pre-revenue, publicly traded biotech, its strategy hinges on validating its platforms through clinical proof-of-concept to attract partnership and development capital.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed